Table 3.

Diagnostic performance of 6-month biomarkers to discriminate 12-month complete renal response from no response in the training and validation cohorts

Biomarker	Cohort	Sensitivity	Specificity	PPV	NPV	+LR	−LR
uCD163<370 ng/mmol	Training cohort	0.90	0.87	0.87	0.90	6.95	0.12
	Validation cohort	0.87	0.89	0.91	0.84	7.82	0.15
uPCR<0.5 g/g	Training cohort	0.52	0.97	0.94	0.68	16.0	0.22
	Validation cohort	0.48	1.00	1.00	0.60	a	0.52
uPCR<1.5 g/g	Training cohort	0.86	0.81	0.81	0.86	4.45	0.17
	Validation cohort	0.87	0.89	0.91	0.84	7.82	0.15
25% uPCR reduction	Training cohort	0.86	0.65	0.69	0.83	2.43	0.21
	Validation cohort	0.87	0.56	0.71	0.77	1.96	0.23
Anti-dsDNA antibody disappearance	Training cohort	0.66	0.48	0.54	0.60	1.27	0.71
	Validation cohort	0.70	0.56	0.67	0.59	1.57	0.55
25% anti-dsDNA antibody reductionb	Training cohort	0.83	0.45	0.59	0.74	1.51	0.38
	Validation cohort	—	—	—	—	—	—
C3 normalization	Training cohort	0.76	0.55	0.61	0.71	1.68	0.44
	Validation cohort	0.70	0.67	0.73	0.63	2.09	0.46
25% C3 increase	Training cohort	0.76	0.68	0.69	0.75	2.35	0.36
	Validation cohort	0.65	0.72	0.75	0.62	2.35	0.48

PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; −LR, negative likelihood ratio.

^aThe denominator is zero.

^bAnti-dsDNA antibody values were only available as positive/negative from the validation cohort.